Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

[...] ac function: Left ventricular ejection fraction (LVEF) ≥55% with no obvious abnormality in electrocardiogram; Renal function: eGFR≥30ML/min/1.73m2； (For patients with a [...] irolimus, leflunomide, telitacicept, Beliumab, and rituximab,etc,al); or Intolerant to standard treatments; or the dosage of st [...] -hour urine protein quantification ≥500mg or UPCR≥0.5mg/mg; ≥ >50% decline in eGFR within 3 months; Patients who are unable [...] medical condition that would prevent the administration of anti-CD19 CAR NK Cells (KN5501)KN5601, except for lupus (determined by the investigator) Received [...]

[...] hropathy(MCD) or focal segmental glomerulosclerosis (FSGS); IgA nephropathy Age: ≥ 5 years old, male or female; IgA nephropathy pathologically confirmed by renal biopsy; Angiotensin-Converting Enzyme Inhibitors (ACE) or angiotensin receptor blocker (ARB) treated for at least 3 months and meet at least one of the following requirements: Combination or sequent [...] Exclusion Criteria: Subjects with known severe allergic reac [...]

[...] e, there is a pressing need for new therapeutic strategies. Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Although immunosuppressants have been used in some patients, IgAN remains a leading cause of kidney failure in young adults, with approximately 40% of patients progressing to end-stage kidney disease (ESKD) [...] Since 2019, CAR T-cell therapy has shown success in treating [...] volutionizing the treatment of refractory SLE and MDR-SRNS, IgAN, offering new hope for patients with these challenging conditions.